

Standard Operating Procedure

Management of intervention group patients

Authors: FLO-ELA Trial Management Group

Authorisation: Mark Edwards (Chief Investigator)

Scope

- To provide guidance on management of patients who have been allocated to the intervention group in the FLO-ELA Trial.
- The procedures for administering the intervention are described in detail below and a summary is provided on page 5.

Procedure

- The trial intervention period will commence at the start of general anaesthesia and continue for six hours after surgery is complete (maximum total duration: 24 hours).
- In patients already fully sedated and intubated before arrival in the theatre suite, the trial intervention period will commence when the patient arrives in the anaesthetic room / theatre.

Cardiac output monitoring

- Investigators may only use commercially available cardiac output monitoring equipment which displays cardiac stroke volume values and accurately track changes in these values. Suitable technologies are:
 - Arterial pressure waveform analysis (LiDCO Rapid, LiDCO Plus, Edwards Lifesciences EV1000/FloTrac)
 - Oesophageal Doppler (Deltex ODM/ODM+)
- Immediately following induction of anaesthesia, the selected system will be set up for monitoring of cardiac output. In patients already fully sedated and intubated before arrival for surgery, the selected system should be set up as soon as possible after arrival in the anaesthetic room / theatre.
- If investigators wish to give more than 500ml of fluid boluses in the anaesthetic room / theatre before the induction of anaesthesia, it is recommended that this is guided by cardiac output monitoring.

Doc Ref: SOP 001
Version 1.0

- Delays in setting up cardiac output monitoring should be avoided. If monitoring has been used for less than 80% of the intervention period, this should be reported as a protocol deviation.

General haemodynamic measures

Care for all patients has been loosely defined to avoid extremes of clinical practice but also practice misalignment, as follows:

- During the intervention period, patients will receive one of the following fluids at 1 ml/kg/hr as maintenance fluid:
 - 5% dextrose
 - 4% dextrose with 0.18% NaCl (+/- KCl)
 - 5% dextrose with 0.45% NaCl (+/- KCl)

It is recommended that this maintenance fluid is delivered at a fixed rate using an infusion device. Routine maintenance requirements should meet NICE guidance (20-30ml/kg/day of water, approximately 1mmol/kg/day of potassium, sodium and chloride and 50-100g/day of glucose). In certain clinical scenarios such as electrolyte imbalance, an alternative fluid may be selected at the clinician's discretion. For obese patients, the maintenance fluid rate should be adjusted to the ideal body weight (1). A calculator is available within the NELA webtool.

- Additional fluid will be administered at the discretion of the clinician, guided by the pulse rate, arterial pressure, urine output, core-peripheral temperature gradient, serum lactate and base deficit/excess.
- Blood will be transfused at clinicians' discretion but should maintain haemoglobin at greater than 8 g/dl.
- Oxygen will be administered to achieve a target SpO₂ of ≥94%.
- Core temperature will be maintained between 36.5°C and 37.5°C.
- Mean arterial pressure will be maintained between 60 and 100 mmHg using an alpha adrenoceptor agonist or vasodilator as required, although other measures such as adjustments to anaesthesia and analgesia should be considered first.

Post-operative analgesia

- Post-operative analgesia will be provided at the discretion of the clinician in accordance with local protocols.

Administering fluid to a stroke volume end-point

- Currently, peri-operative intra-venous fluid is usually administered to subjective end-points. The use of stroke volume as a treatment end-point may significantly reduce but not eliminate this subjectivity. However, the measurement of stroke volume does not replace the discretion of the treating clinician in ensuring patient safety. The protocol allows for the treating clinician to adjust both the volume and type of fluid administered, e.g. if there is concern about persistent hypovolaemia or fluid overload. Such decisions may relate to clinical circumstances or physiological measurements (e.g. pulse rate, arterial pressure, urine output, serum lactate, base excess).
- Stroke volume and stroke volume variation will be determined by the cardiac output monitoring system. In order to ensure a standardised approach to fluid administration, no more than 500ml of intra-venous fluid will be administered prior to commencing cardiac output monitoring.
- Patients will receive 250ml fluid challenges, each given over a five minute duration, of one of the following solutions, aiming to maximise stroke volume:
 - “Balanced” crystalloid: Hartmann’s solution (compound sodium lactate, Ringer’s lactate), Plasmalyte 147.
 - 0.9% sodium chloride
 - Gelatin-based colloid
 - Albumin
- Maximal stroke volume is defined as the absence of a rise in stroke volume of at least 10% sustained for 20 minutes or more in response to a fluid challenge (see flowchart). Thus in the absence of such a rise in stroke volume, further fluid challenges are unlikely to be helpful at that time.
- Once the maximal value of stroke volume is determined, this should be maintained throughout the intervention period with fluid boluses as required. Initial increases in stroke volume are often only transient. If stroke volume does not increase as defined above, it is likely that the heart is functioning on the horizontal part of the Starling curve (see figure). This suggests the patient is not hypovolaemic and fluid challenges should be stopped. If the stroke volume decreases, this is most likely due to ongoing fluid losses and a further fluid challenge is required.
- Stroke volume **variation** (SVV) should also be monitored. After the initial fluid bolus, SVV should be checked prior to each subsequent planned fluid bolus (see flowchart). An SVV less than 5% suggests that fluid responsiveness is unlikely, so a fluid bolus is not recommended.
- Many peri-operative physiological changes may alter the maximal value of stroke volume. These may be due to general and regional anaesthesia, surgical stimulation, endotracheal tube removal, pain, fluid loss, etc. Further fluid challenges should be considered where there is reason

to believe the maximal stroke volume may have changed. The most challenging situation is the patient who clearly remains stroke volume responsive despite large volumes of intra-venous fluid. This arises when an evolving severe fluid deficit has yet to become clinically apparent in any other respect e.g. haemorrhage. Experience from previous trials suggests that it is particularly important to continue to give fluid challenges in such patients to maintain maximal stroke volume. The small volume of each individual fluid challenge will minimise any potential adverse effects of confirming volume status in euvolaemic patients. Data from previous studies confirm the safety of this approach.




Figure: Starling's curve
 The increase in venous return due to intra-venous fluid (red arrows) increases stroke volume in responsive patients. At maximal stroke volume (horizontal part of curve), the absence of a response indicates fluid is not required.

What if blood products or intravenous fluids are required for indications unrelated to changes in stroke volume?

- Many intervention group patients will require blood products and, in some cases, additional intravenous fluid challenges may be requested by a clinician. Administration of fluid, blood or blood products under these circumstances should be performed with stroke volume monitoring and these data should be used to inform the need for subsequent fluid challenges.


Other aspects of care

- All other aspects of care should be in line with local protocols and recommendations on the care of emergency laparotomy patients by the National Emergency Laparotomy Audit (2).

References

1. NICE. Intravenous fluid therapy in adults in hospital (Clinical Guidance 174). 2014. Available from: <http://www.nice.org.uk/>
2. NELA project team. The Second Patient Report of the National Emergency Laparotomy Audit. 2016. Available from: <http://nela.org.uk/reports>

FLO-ELA intervention flowchart



- General haemodynamic measures (all patients)
1. Maintenance fluid at 1 ml/kg/hr
 2. Transfuse blood to maintain haemoglobin >80 g/l
 3. Clinician retains discretion to adjust therapy if concerned about risks of hypovolaemia or fluid overload
 4. Mean arterial pressure 60-100 mmHg; SpO₂ ≥94%; temperature 36.5 – 37.5°C